Amylyx Pharmaceuticals, Inc.
AMLX
Rangering i aksjer
#4246
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Aksjekurs
$29.32
Sist synkronisert: 2026-10-21
Markedsverdi
$3.68B
Endring (1 dag)
1.91%
Endring (1 år)
97.84%
Land
US
Handel Amylyx Pharmaceuticals, Inc. (AMLX)
Kategori
Healthcare
Aksjeprishistorikk for Amylyx Pharmaceuticals, Inc. (AMLX)
Høyeste sluttskurs: $27.68 den 2026-10-01
Laveste sluttskurs: $19.75 den 2022-01-01
Laveste sluttskurs: $19.75 den 2022-01-01
Aksjeprishistorikk for Amylyx Pharmaceuticals, Inc. fra 2022 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | 41.29% |
| 2025 | 192.53% |
| 2024 | -69.40% |
| 2023 | -60.37% |
| 2022 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $758.21 | 7.77% |
CH
|
